Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2018 Financial Results


Fourth Quarter 2018 Revenues Grew 72% to $5.7 Million; Fiscal Year 2018 Revenues Increased 17% to $21.2 Million


Fourth Quarter 2018 Gross Margins Expanded to 50.5%; Annual Gross Margins Expanded to 48.6%


DAVIS, Calif. – March 14, 2019 – Marrone Bio Innovations Inc. (NASDAQ: MBII) (MBI), an international leader in smart biopesticide and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2018.


Selected Operating and Financial Highlights


$ in millions  Q4
   % Increase
   % Increase
Revenues*  $5.7   $3.3    72%  $21.2   $18.2    17%
Gross Profit  $2.9   $1.5    89%  $10.3   $7.6    35%
Gross Margin   50.5%   46.0%   10%   48.6%   42.0%   16%
Operating Expenses  $8.3   $6.6    25%  $29.8   $30.6    (3)%
Loss from Operations  $(5.4)  $(5.1)   6%  $(19.5)  $(23.0)   (15)%
Net Loss**  $(8.0)  $(7.4)   9%  $(20.2)  $(30.9)   (35)%
Cash Used in Operations  $(2.8)  $(6.6)   (58)%  $(19.6)  $(21.1)   (7)%


*Because revenues in Full Year and Fourth Quarter 2018 included the effect of the adoption of the ASC 606 accounting standard (Revenue From Contracts With Customers), year-over-year numbers are not strictly an apples-to-apples comparison.


** Includes adjustments related to revisions to accounting assessment of Financing Transaction closed in Q1.


Q4 2018 Financial Highlights


Revenues in the fourth quarter of 2018 improved by 72 percent to $5.7 million, compared with $3.3 million in the fourth quarter of 2017, primarily because of higher sales of the Venerate product family.
  The beneficial mix effect of increased sales of the Venerate product family in the fourth quarter of 2018 also increased gross margins significantly to a record 50.5 percent, compared with 46 percent in the fourth quarter of 2017.
Operating expenses were $8.3 million in the fourth quarter of 2018, compared with $6.6 million in the fourth quarter of 2017, and reflected the investment in the sales and marketing organization.
Net loss in the fourth quarter of 2018 was $8.0 million, or $(0.07) per share, compared with a net loss of $7.4 million, or $(0.24) per share, in the fourth quarter of 2017.
Cash used in operations for the quarter was $2.8 million, down from $6.6 million in the fourth quarter of 2017.




FY 2018 Financial Highlights


Revenues grew to $21.2 million in 2018, a 17 percent increase compared with $18.2 million in 2017, as sales of the current portfolio of products expanded both with current customers and across new crops and geographies.
  Gross margins expanded to 48.6 percent in 2018, compared with 42 percent in 2017, reflecting a favorable mix effect from higher sales of the Venerate product family.
Full-year operating expenses were $29.8 million in 2018, compared with $30.6 million of operating expenses in 2017.
  Net loss improved by $10.7 million to a loss of $20.2 million, or $(0.20) per share, reflecting revenue growth and higher gross margins.
  Net loss for fiscal year 2018 was affected by several revisions to other income (expense), as related to the benefit of lower interest expense as well as the one-time effect of changes in the fair value of financial instruments and the gain and loss on extinguishment of debt. In particular, the revision related to the accounting assessments for the Company’s February 2018 financing transactions. The net effect of the change is a decrease in other income and expense of $2.3 million, and an increase in net loss by the same amount. This non-cash change does not affect operating results.
  Cash used in operations was $19.6 million in 2018, down from $21.1 million in 2017.


Management Commentary


“We not only stabilized our commercial operations and financial footprint in fiscal year 2018, but we did so as we grew revenues and expanded gross margins,” said Dr. Pam Marrone, chief executive officer of Marrone Bio Innovations. “As we move forward in 2019, we are focused on three key deliverables: One, portfolio optimization; two, market expansion; and three, accelerated innovation. We see 2019 as a pivotal year as the groundwork we’ve put in place—technically, commercially and financially—comes to fruition with continued substantial revenue growth, which also sets the stage for growth in 2020 and beyond.”


“Marrone Bio’s technical successes are complemented by a disciplined approach to capitalizing our product pipeline, launching our commercial products and improving our manufacturing efficiencies, all while investing our cash strategically and judiciously,” she added. “Coupled with last year’s financing transactions, we are well positioned as the commercial leader in biologically based agricultural solutions.”




Q4 2018 Operational Highlights


  Launched TerraConnect, a new global biological soil-applied and seed-treatment platform, delivering growers high-performance products as well as a broad range of valuable tools to improve and protect crops.
Expanded MBI’s international distribution network through a new agreement with Hop Tri Investment Corporation in Vietnam and Cambodia, with AMC/Agrimatco in Turkey for Grandevo, Majestene and/or Regalia and with Kyung Nong Corporation for Majestene and Venerate in South Korea.
Received notice of allowance from the U.S. Patent and Trademark Office for claims covering MBI-110 bacterium, the active ingredient in Stargus and Amplitude biofungicides, together covering nearly all potential commercial embodiments.
  MBI-110 Biofungicide (Stargus) and Haven Sun Protectant approved for sale in Canada for use in fruits and vegetables (Stargus) and fruits, vegetables and nuts (Haven).


Conference Call and Webcast


Management will host an investor conference call at 1:30 p.m. PDT (4:30 p.m. EDT) today, March 14, 2019, to discuss Marrone Bio Innovations’ fourth quarter and full year 2018 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information:


Q4 2018 Conference Call and Webcast

Date: Thursday, March 14, 2019

Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)

U.S. Dial-in: 1-800-263-0877

International Dial-in: 1-323-794-2094

Conference ID: 7937030



Please dial in at least 10 minutes before the start of the call to ensure timely participation.


A playback of the call will be available through April 13, 2019. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 7937030. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: MBII Q4 2018 Webcast.


About Marrone Bio Innovations


Marrone Bio Innovations Inc. (NASDAQ: MBII) strives to lead the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that support a better tomorrow for farmers, turf managers and consumers around the globe. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies to rapidly develop seven effective and environmentally responsible pest management products to help customers operate more sustainably while uniquely improving plant health and increasing crop yields. Supported by a robust portfolio of over 400 issued and pending patents around its superior natural product chemistry, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude™; TerraConnect™; and Zelto® and Zequanox®, all of which are trademarks or registered trademarks of Marrone Bio Innovations.




Learn more about Marrone Bio Innovations at We also use our investor relations website,, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.


Marrone Bio Innovations Forward Looking Statements


This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding management’s proposed deliverables for 2019, the Company’s positioning for becoming a commercial leader, and the potential benefits of the Company’s products. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the Securities and Exchange Commission. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.


Marrone Bio Innovations Contacts:

Pam Marrone, CEO and Founder

Jim Boyd, President and CFO

Telephone: +1 (530) 750-2800



Investor Relations:

Greg Falesnik

Managing Director

MZ Group – MZ North America

Main: 949-385-6449





Condensed Consolidated Balance Sheets

(In Thousands, Except Par Value)


   DECEMBER 31, 
   2018   2017 
Current assets:          
Cash and cash equivalents  $18,221   $786 
Restricted cash, current portion       487 
Accounts receivable   2,720    3,785 
Inventories, net   8,224    9,827 
Deferred cost of product revenues   4    3,063 
Prepaid expenses and other current assets   967    1,170 
Total current assets   30,136    19,118 
Property, plant and equipment, net   14,512    16,016 
Restricted cash, less current portion   1,560    1,560 
Other assets   359    219 
Total assets   46,567   $36,913 
Liabilities and stockholders’ equity (deficit)          
Current liabilities:          
Accounts payable  $1,692    3,800 
Accrued liabilities   6,872    8,189 
Accrued interest due to related parties       1,622 
Deferred revenue, current portion   438    6,193 
Derivative liability       674 
Debt, current portion   2,318    1,524 
Total current liabilities   11,320    22,002 
Deferred revenue, less current portion   2,399    2,046 
Debt, less current portion   11,819    24,407 
Debt due to related parties   7,300    37,822 
Other liabilities   794    1,287 
Total liabilities   33,632    87,564 
Commitments and contingencies          
Stockholders’ equity (deficit):          
Preferred stock: $0.00001 par value; 20,000 shares authorized and no shares issued or outstanding at December 31, 2018 and December 31, 2017        
Common stock: $0.00001 par value; 250,000 shares authorized, 110,686 and 31,351 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively   1     
Additional paid in capital   296,409    214,921 
Accumulated deficit   (283,475)   (265,572)
Total stockholders’ equity (deficit)   12,935    (50,651)
Total liabilities and stockholders’ equity (deficit)  $46,567   $36,913 





Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Amounts)


   2018   2017 
Product  $20,775   $17,935 
License   445    232 
Total revenues   21,220    18,167 
Cost of product revenues   10,907    10,528 
Gross profit   10,313    7,639 
Operating Expenses:          
Research, development and patent   10,679    10,820 
Selling, general and administrative   19,139    19,814 
Total operating expenses   29,818    30,634 
Loss from operations   (19,505)   (22,995)
Other income (expense):          
Interest expense   (2,060)   (3,374)
Interest expense, related parties   (451)   (4,355)
Change in fair value of financial instruments   (5,177)   (96)
Loss on extinguishment of debt, net   (2,196)    
Gain on extinguishment of debt, related party   9,183     
Other income (expense), net   (8)   (105)
Total other income (expense), net   (709)   (7,930)
Net loss  $(20,214)  $(30,925)
Basic and diluted net loss per common share:  $(0.20)  $(1.06)
Weighted-average shares outstanding used in computing basic and diluted net loss per common share:   101,248    29,235 





Condensed Consolidated Statements of Cash Flows

(In Thousands)


   2018   2017 
Cash flows from operating activities          
Net loss  $(20,214)  $(30,925)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   1,890    2,044 
Gain on disposal of equipment       363 
Share-based compensation   1,850    2,114 
Non-cash interest expense   885    1,596 
Change in fair value of financial instruments   5,177    96 
Loss on extinguishment of debt, net   2,196     
Gain on extinguishment of debt, related party, net   (9,183)    
Net changes in operating assets and liabilities:          
Accounts receivable   1,065    (193)
Inventories   1,603    (1,345)
Prepaid Expenses and other assets   (60)   (144)
Deferred cost of product revenues   1    (375)
Accounts payable   (2,028)   2,305 
Accrued and other liabilities   (855)   2,599 
Accrued interest due to related parties   (1,614)   4 
Deferred revenue   (339)   805 
Net cash used in operating activities   (19,626)   (21,056)
Cash flows from investing activities          
Purchases of property, plant and equipment   (579)   (849)
Proceeds from the sale of equipment       35 
Net cash used in investing activities   (579)   (814)
Cash flows from financing activities          
Proceeds from issuance of common stock, net of offering costs   34,486    8,188 
Proceeds from issuance of debt   2,000    4,000 
Proceeds from secured borrowings   21,844    16,228 
Reductions in secured borrowings   (21,046)   (14,952)
Repayment of debt   (254)   (756)
Financing costs       (215)
Repayment of capital leases       (420)
Exercise of stock options   39    17 
Net settlement of options   (14)    
Exercise of warrants   98     
Net cash provided by financing activities   37,153    12,090 
Net increase in cash and cash equivalents and restricted cash   16,948    (9,780)
Cash and cash equivalents and restricted cash, beginning of period   2,833    12,613 
Cash and cash equivalents and restricted cash, end of period  $19,781   $2,833 
Supplemental disclosure of cash flow information          
Cash paid for interest  $2,915   $5,993 
Supplemental disclosure of non-cash investing and financing activities          
Property, plant and equipment included in accounts payable and accrued liabilities  $194   $245 
Equipment acquired with debt  $487   $ 
Embedded derivative liability associated with bridge loan  $573   $ 
Conversion of debt to equity  $10,000   $ 
Conversion of bridge loan (convertible note) to equity  $6,000   $ 
Conversion of debt, related party to equity  $35,000   $ 
Conversion of accrued liabilities into equity associated with the granting of restricted stock units  $205   $ 





View differences made from one to another to evaluate Marrone Bio Innovations Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Marrone Bio Innovations Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Log in with your credentials


Forgot your details?

Create Account